Introduction
Prostate cancer is the most common malignancy in men in the USA as well as in the Western world as a whole, and is the second most frequent cause of cancer deaths after lung cancer [1] . Palliative hormonal therapy aimed at androgen ablation by either surgical or chemical orchiectomy with or without the addition of peripheral androgen receptor blockers is the current standard treatment for advanced tumors. Objective and biochemical responses in up to 70% of patients are usually seen with progression-free survivals of approximately 12-18 months, Eventually, however, all patients progress or relapse [2] . Further hormonal maneuvers in this 'hormone-refractory' population achieve occasional responses, generally short-lived [3] . Non-hormonal approaches have been widely successful in recent years, generating a number of study protocols of single-agent and combination regimens including, among others, estramustine, suramin and paclitaxel, with no clear evidence of improved survival, and usually at the expense of increased toxicity, economic costs and in some instances greater patient discomfort [4] [5] [6] .
Estrogen therapy has long been recognized as a very active first-line modality, but due to excessive treatmentrelated cardiovascular and thromboembolic deaths in the VACURG studies using high doses of diethystilbestrol (DES), it was largely removed from up-front and subsequent treatment lines [7] . Fosfestrol, a DES prodrug developed to achieve higher water solubility and lower toxicity, is capable of producing higher intracellular levels of DES with significant antitumor activity, and can be administered easily by the oral route [8] . Because of the previously described activity of fosfestrol and its manageable toxicity we have administered it in the second-or third-line treatment of advanced prostate cancer. In the present paper we describe the results obtained with low-dose continuous oral fosfestrol in a population of so-called 'hormone-refractory' prostate carcinoma patients treated at our institution.
Patients and methods

Patients
This retrospective study comprises 38 patients treated at the Alexander Fleming Institute between October 1992 and February 1998. Prostate cancer patients registered in our data base were selected for this analysis provided they had histologically-confirmed diagnoses of prostate carcinoma; >2 prior hormonal therapies including surgical or chemical orchiectomy; progressive disease as indicated by two consecutively rising PSA determinations; 'anti-androgen withdrawal' effect ruled out prior to treatment start; no other concomitant chemo or hormonal therapies; adequate drug intake and laboratory assessment at one month. Data were retrieved from individual medical records.
Evaluations
Patients were evaluated at baseline by medical history, physical examination, determination of the presence or absence of disease-related symptoms, PSA measurement, and routine laboratory profiles. These evaluations were repeated monthly during the follow-up period. Most patients had baseline serum testosterone determinations and radionucleide bone scans.
Response criteria
Response was assessed by serial (monthly) PSA measurements. Partial response (PR) was defined as a 50% decrease from baseline, and complete response (CR) was defined as normalization of PSA, both sustained for at least one month (two consecutive determinations) in the absence of clear evidence of worsening or the appearance of new signs of disease.
Patients with less than a 50% decrease in PSA were considered non-responders. Progressive disease was defined as two consecutively rising PSA measurements or the appearance of new signs of disease.
Symptomatic evaluation was assessed by patient-reported pain scores.
Treatment schedule
Fosfestrol was given orally at an initial dose of 100 mg 3x daily, continuously, until the advent of progressive disease or excessive toxicity. All ongoing hormonal or cytotoxic therapy was discontinued prior to the start of fosfestrol. In the few patients with a single PSA rise following an initial response, double-dose fosfestrol was administered; this was not considered progressive disease. Treatment, as with the initial dose, was again continued until progressive disease (defined as two consecutive rises of PSA over the lowest achieved value), or excessive toxicity.
Symptomatic treatment included non-steroidal anti-inflammatory drugs, corticosteroids and external beam radiotherapy as needed; however, no standard protocol was used.
Statistical considerations
The primary objective of this study is to determine antitumor activity as determined by PSA-defined response, and secondary end-points are assessment of symptomatic control and survival duration.
Progression-free survival and overall survival were calculated from treatment start until two progressively-rising PSA measurements or death (or last contact), respectively. Duration of response was measured from first documentation of response until two progressively rising PSA measurements. Survival curves were plotted according to the Kaplan-Meier method.
Results
All 38 patients included in the study were evaluated for response, toxicity and survival.
The patient characteristics are listed in Table 1 . All patients had undergone prior orchiectomy [surgical 23%, chemical 92%, (in some cases both)], and all had received an antiandrogen (flutamide 86%, cyproterone 71%) followed by withdrawal maneuvers or further therapy in 56% (with other hormonal agents, estramustine or other chemotherapy agents or ketokonazol), for a median of 3 prior systemic treatment lines (range 2-6) and a median time on systemic treatment of 20 months (range 5-97). Most patients (73%) were symptomatic at treatment start.
As of 1 November 1998, 35 patients have progressed and 32 have died. For the remaining 6 patients the median follow-up is 23 months (range 16-35).
Toxicity
The predominant toxicities are listed in Table 2 .
Two patients died of unrelated causes (one of concomitant lung cancer, one of cerebral hemorrhage). No treatment-related deaths were observed. As expected, the most common adverse events seen were related to the hormonal effects of fosfestrol (appearence or worsening of pre-existing gynecomastia and fluid retention). Three patients developed deep vein thrombosis (DVT) (8%). Two of them were evaluated at the same time as non-responders and their treatment was stopped; the remaining patient received appropriate anticoagulant therapy and continued on fosfestrol. There was no discontinuation of fosfestrol due to toxicity.
Therapeutic activity
PSA-defined responses were observed in 31 patients, for an overall response rate of 79% (95% confidence interval (95 CI): 66%-92%). Eight had normalization of PSA levels (CR rate 21%) and twenty-three had 3=50% decrease in PSA levels (PR rate 58%) ( Table 3 ). The median duration of response was 3.5 months (range 1-18), and was longer for CRs than PRs (10 vs. 4 months) although this did not reach statistical significance (P = 0.07).
The median time to response was one month. Potentially predictive factors for response were analyzed by the chi-square test. Age, grade, PSA level at treatment start, presence or absence of extra-osseous disease, baseline hemoglobin, duration of prior treatment and number of prior treatment lines were not significant. Only prior surgical orchiectomy as compared with chemical orchiectomy achieved borderline statistical significance (P = 0.049) as a predictor of worse response probability (55% vs. 86%). This, however, was not associated with worse survival (P -0.094).
Objective response evaluation was not considered prospectively as a primary end-point, so an accurate report is not possible. Because patients were re-evaluated by bone scan or CT scan only if they had new symptoms or rising PSA levels, progressions were more likely to be documented than responses. Nevertheless, we anecdotally recorded objective responses in lymph node (inguinal, supraclavicular and retroperitoneal) (two patients) and lung metastases (one case), as well as decrease in the size of papable hepatomegaly (in one case).
Median time to progressive disease was 7 months (range 2-34 months).
Symptomatic response assessment revealed that 53% 
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of patients had improved pain statuses, but one-third of them had also received palliative radiotherapy (leaving 39% of symptomatic responders if irradiated patients are excluded), 34% remained stable and 13% reported worsened symptomatology.
Survival
The overall survival curve is shown in Figure 1 . The median survival for all patients was 12 months. Patients showing PSA-defined response had significantly longer survivals than those with no response (P < 0.05 by Mantel-Haentzel test). Responders had a median survival of 13 months compared to 7 months for nonresponders. The median survivals for complete responders and partial responders were 22 and 9 months, respectively (P -NS). Baseline hemoglobin level lower or higher than 12 gr% was a significant predictor for overall survival (9 months vs. 25 months, P = 0.015 by log-rank).
Discussion
This retrospective analysis was undertaken to assess the results with low-dose continuous oral fosfestrol seen in our population of advanced 'hormone-refractory' patients using PSA-defined responses as primary endpoint. This patient population is usually considered for non-hormonal approaches and experimental chemotherapy protocols. The significant cost of some and the toxic effects of others of these schedules prompted us to analyze carefully a policy of pursuing hormonal maneuvers and select patients who would not require more complex treatments for control of their disease. The value of assessing antitumor activity by means of declining PSA levels is a matter of debate [9] . However, except for drugs that clearly interfere with the production or secretion of this molecule (e.g., Suramin), most of the recent studies in this setting accept PSA response as a surrogate marker for objective responses associated with improved survival in some of them [10] [11] [12] . In our study over three-quarters of our patient population, who would clearly fit the various proposed definitions of 'hormone-refractory' prostate cancer, achieved biochemical responses of clinically meaningful duration, accompanied by symptomatic improvement or stabilization (albeit the relative contributions of specific and supportive treatment are indistinguishable) and evidence of improved survival for responding patients. Toxicity was as expected for estrogen-based therapy. We recognize that prior studies with estrogens have produced increased risk of death from cardiovascular disease, and therefore the toxic effects of estrogens should not be minimized. The VACURG studies alluded to, however, were performed with high-dose DES, not fosfestrol. The rate of DVT (8%) may seem high, but is consistent with the results seen in patients treated with estramustine phosphate [6, 18, 19] . We feel that a trial of prophylaxis with anticoagulants would be appropiate in a prospective setting, at least for patients with predisposing factors. Gynecomastia is a troublesome side effect, although in our experience none of the patients required palliative radiotherapy or mastectomy.
A previous small study in the pre-PSA era had evaluated the effects of high-dose intravenous fosfestrol in patients who had failed hormonal therapy. Response was assessed by a variety of criteria but was reported as limited, since only 17% (3 out of 18) showed a response based on an acid phosphatase decline greater than 50% sustained over three months. Of note, in this study toxicity was severe and treatment was discontinuted in four patients because of adverse events [13] . The same group however, reported that a similar schedule of fosfestrol combined with adriamycin had produced 50% of acid phosphatase responses among 19 patients. More recently other investigators have verified the activity of high-dose intravenous fosfestrol in this setting [14] .
Low-dose continuous oral schedules have not been reported in similar detail.
The degree of activity seen in our study could be explained by a variety of mechanisms: a) Patient selection. Given the retrospective nature of this study series, all of the biases attributable to restrospective studies may apply. It is not possible to rule out this explanation. b) Inadequate prior treatment or androgen-sensitive patients. The fact that all patients had prior castration (either surgical or chemical), with documented castrate serum levels of testosterone at fosfestrol start in every patient who had this measurement done, and the rather heavy prior hormonal treatment (median of 3 prior treatment lines) make this possibility very unlikely.
c) The oral continuous schedule used. d) A more profound hormonal inhibition generated by estrogens than by other hormonal maneuvers. Although testosterone nadir levels tend to be lower in patients treated with estrogens than those treated with LHRH agonists or surgical castration, it is difficult to justify this degree of activity in already castrated patients [15] . We did not perform repeated testosterone levels in our patients to confirm or reject this possibilty. e) A non-hormonal mechanism of action of fosfestrol. On this subject a number of pre-clinical investigations have shown that estrogens are capable of inducing apoptosis and cell cycle arrest in prostate cancer cells independently of estrogen receptor level. Others have identified microtubule disruptions in cells treated /// vitro with DES, suggesting a mechanism of action similar to that of spindle poisons such as colchicinc and estramustine [16, 17] . Too few patients in our series are evaluable to assess the activity of fosfestrol in the setting of prior estramustine-based treatment to serve as a basis of any assumptions about cross-resistance or mechanisms of action. Of note, two prior responders and one patient with prior progression to estramustine responded to fosfestrol.
Regardless of the explanation(s) proposed, the degree of activity seen in our series warrants further prospective evaluation of fosfestrol in this schedule as a single agent and in combination therapy, since it compares favourably in terms of response, survival and symptomatic benefit as well as of toxicity, costs and ease of administration with many other regimens developed for patients with HRPC [4] [5] [6] [10] [11] [12] [18] [19] [20] [21] [22] [23] (Table 4) .
We consider that the current definition of hormonerefractoriness does not exclude the probability of responding to estrogen therapy. If the responses seen in this setting are due to hormonal effects of estrogens the defining term should be modified from 'hormone-refractory' to 'androgen-insensitive'.
This schedule of low-dose oral continuous fosfestrol is a feasible, safe and effective treatment choice for patients with advanced hormone-refractory prostate cancer, applicable to a wide range of patients in this setting.
The role of estrogens in the current management of prostate cancer should be reconsidered and redefined.
